---
title: "Understanding the Market | CUTIA-B surged over 14% in early trading, strategic adjustments affected first-half performance, plans to raise funds through a placement to increase investment in R&D and commercialization"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255109472.md"
description: "CUTIA-B rose over 14% in early trading, reaching HKD 10.91, with a transaction volume of HKD 29.0652 million. The company's revenue in the first half of the year decreased by 30.6% year-on-year to approximately HKD 66.3 million, with a net loss of approximately HKD 239 million, an increase of about 19.1% year-on-year. Due to the impact of macro policies, it terminated its agency cooperation with the American skincare brand OMA and shifted resources towards the commercialization of new products. CUTIA plans to issue 28.904 million placement shares at a price of HKD 8.40 per share, with the proceeds to be used for research and development and marketing"
datetime: "2025-08-29T02:31:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255109472.md)
  - [en](https://longbridge.com/en/news/255109472.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255109472.md)
generator: "portal-rs"
---

# Understanding the Market | CUTIA-B surged over 14% in early trading, strategic adjustments affected first-half performance, plans to raise funds through a placement to increase investment in R&D and commercialization

According to Zhitong Finance APP, CUTIA-B (02487) rose over 14% in early trading, and as of the time of writing, it has increased by 14.24%, trading at HKD 10.91, with a transaction volume of HKD 29.0652 million.

In terms of news, CUTIA announced its interim results, reporting a 30.6% year-on-year decrease in revenue to approximately HKD 66.3 million for the first half of the year; the net loss was approximately HKD 239 million, an increase of about 19.1% year-on-year. The announcement stated that the revenue decline was mainly due to the group's prudent decision to terminate its agency cooperation with the American skincare brand OMA under the influence of macro policies and the international environment, reallocating resources to the commercialization preparations of new products such as CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam), which have already received regulatory approval. These new products are expected to have greater market potential and a higher return on investment, and this adjustment is anticipated to benefit the group's medium to long-term development.

In addition, CUTIA announced plans to issue a total of 28.904 million placement shares at a placement price of HKD 8.40 per share, representing a discount of approximately 12.04% compared to the closing price of HKD 9.55 per share on the previous trading day. The net proceeds from the placement are expected to be approximately HKD 240 million, with 45% allocated for preclinical research and development, clinical trials, and production facility layout in areas such as localized fat accumulation management, hair diseases and care, skin diseases and care, and epidermal anesthesia; another 45% will be used for market promotion, channel expansion, and brand building for CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam); the remaining 10% will be used for working capital and general corporate purposes

### Related Stocks

- [02487.HK](https://longbridge.com/en/quote/02487.HK.md)

## Related News & Research

- [Xinyi Solar unit Xinyi Energy plans sale or injection of solar farms into PRC-listed REIT](https://longbridge.com/en/news/297026248.md)
- [Yunnan Jinxun Resources FY26 H1 profit jumps 70.55% to RMB 230.2 million; revenue rises 49.94% to RMB 1.45 billion](https://longbridge.com/en/news/297051051.md)
- [13:27 ETPatients Representing the Power of Advanced Therapies to Take Center Stage at Emily Whitehead Foundation's 2026 Believe Ball](https://longbridge.com/en/news/297074492.md)
- [AInnovation issues belated disclosure on revised Qingdao ALP earnout terms after 2023-24 shortfall](https://longbridge.com/en/news/297045100.md)
- [Zai Lab’s Interim Results Show Lower Revenue but Rising R&D Investment](https://longbridge.com/en/news/296975726.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**